Date of Completion
2022
Document Type
Research Project
Degree Name
Doctor of Medicine
Keywords
Azithromycin, COBID-19, Randomized Controlled Trial
Abstract
This systematic review on the efficacy of azithromycin in mortality reduction of patients with mild to severe COVID-19 aims to measure the impact of the use of azithromycin in managing COVID-19. Moreover, its safety and risk were also studied in order to tackle the overall picture of the management. For the appraisal, the research group set specific inclusion criteria, which are considered in looking for journal articles tackling the role of azithromycin in COVID-19. This systematic review includes four journal articles for the appraisal; all are randomized controlled trials (RCTs) with a considerable number of participants.
Data extraction and analysis was done using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) as a guide in appraising the specific details from each journal. To measure the certainty of evidence and the risk of bias (ROB), Cochrane Handbook of Systematic Review was used in scoring each of the journals appraised.
Across the four journals included in this review, azithromycin was not associated with any reduction of risk for hospitalization and death. It has however shown a significant role in the management of patients with COVID-19.
No external funding was requested for this systematic review.
First Advisor
Dr. Pearl Elizabeth Contemplacion
APA Citation
Bayoneto, J. M., Bizaba, K. S., Briguela, M. L. A., Claudio, E. C., Gutay, C., Hayase, T. D., Kim, M. J., Olonan, E. K., Pandanan, J. A., Pascua, A. R., Surot, J. M., & Trinidad, M. R. (2022). Azithromycin as part of COVID-19 management and mortality reduction: a systematic review of randomized controlled trials. [Research output, De La Salle Medical and Health Sciences Institute]. GreenPrints. https://greenprints.dlshsi.edu.ph/pharmacology/175/
